Merck KGaA's Lindolrestat Expected To Move To Phase II In 2001
Executive Summary
Merck KGaA expects to bring its aldose reductase inhibitor lindolrestat into Phase II development in the first quarter of 2001.
You may also be interested in...
Par Aims To Add Branded Products After Merck KGaA Divests Equity Stake
Par is looking to add branded products to its portfolio as it seeks to join the top-tier independent generic drug companies after Merck KGaA divests its controlling interest in the firm.
Par Aims To Add Branded Products After Merck KGaA Divests Equity Stake
Par is looking to add branded products to its portfolio as it seeks to join the top-tier independent generic drug companies after Merck KGaA divests its controlling interest in the firm.
Novartis To Launch Anti-Diabetic Starlix In February With Firm's 4,000 Reps
Novartis plans to launch its first anti-diabetic, the type 2 diabetes therapy Starlix, in February using its 4,000 U.S. sales reps. Novartis reps target mostly primary-care physicians and will be trained in the anti-diabetic area.